Bone mass is related to creatinine clearance in normal elderly women

Yendt, Edmund R.; Cohanim, M.; Jarzylo, S.V.; Jones, Glenville; Rosenberg, Gilbert

doi:10.1002/jbmr.5650061005

Cited by 35 publications

(21 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several factors could explain the association between CKD and osteoporosis and osteopenia. Patients with CKD are likely to be older and have lower levels of vitamin D. In addition, there is increasing evidence that CKD itself is a risk factor for low BMD [4][5][6][7]. Patients with impaired renal function have been found to have greater rates of bone loss [7,20].…”

Section: Discussionmentioning

confidence: 99%

“…More than half of individuals older than 70 years have a decreased estimated glomerular filtration rate (eGFR) (<60 mL/min/1.73 m 2 ) [3]. CKD is an independent risk factor for osteoporosis [4][5][6][7]. Individuals with CKD may have an increased risk for osteoporosis for several reasons, including shared risk factors for both conditions such as advanced age and female gender.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Safety of Denosumab for the Treatment of Osteoporosis in Patients with Chronic Kidney Disease

Suzuki¹,

Kihara²,

Mano³

et al. 2017

J Clin Exp Nephrol

View full text Add to dashboard Cite

Background: Chronic kidney disease (CKD) is an independent risk factor for osteoporosis and may lead to metabolic abnormalities that accelerate bone loss. Bisphosphonates, the most widely used treatment for osteoporosis, are contraindicated in patients with severe renal impairment. In the present study, we assessed whether denosumab is a safe and effective treatment for osteoporosis in patients with CKD.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Denosumab for the Treatment of Osteoporosis in Patients with Chronic Kidney Disease

Suzuki¹,

Kihara²,

Mano³

et al. 2017

J Clin Exp Nephrol

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4][5] CKD may have an increased risk for osteoporosis for several reasons, including shared risk factors for both conditions such as advanced age and female gender. Alternatively, CKD may lead to metabolic abnormalities that accelerate bone loss, such as chronic metabolic acidosis, hypogonadism, hyperparathyroidism, and abnormalities with vitamin D metabolism.…”

mentioning

confidence: 99%

The Effect of Raloxifene Treatment in Postmenopausal Women with CKD

Ishani

Blackwell

Jamal

et al. 2008

Journal of the American Society of Nephrology

128

View full text Add to dashboard Cite

It is unknown whether treatment for osteoporosis with raloxifene is safe or effective in those with chronic kidney disease (CKD). With data from a multicenter, randomized, placebo-controlled trial of 7705 postmenopausal women with osteoporosis, the effect of raloxifene on rate of change of bone mineral density (BMD), incidence of fractures, and adverse events by stage of CKD was examined over 3 yr. Baseline serum creatinine values were available for 7316 women, and these values were used to assign a category of creatinine clearance (CrCl) using the Cockcroft-Gault formula (CrCl Ͻ45, 45 to 59, and Ն60 ml/min). BMD was measured at baseline and annually by dual x-ray absorptiometry. Within the placebo group, lower baseline CrCl was associated with a trend for higher annual losses of BMD at the femoral neck; however, within the raloxifene group, lower baseline CrCl was associated with greater increases in femoral neck BMD. This interaction between category of CrCl and treatment assignment was significant for rate of change of BMD at the hip. Irrespective of kidney function, raloxifene treatment was associated with a greater increase in spine BMD, a reduction in vertebral fractures, and no effect on nonvertebral fractures compared with placebo. Within each category of kidney function, adverse events were similar between the raloxifene and placebo groups. In conclusion, raloxifene increases BMD at both the hip and the spine and reduces the risk for vertebral fractures among individuals with CKD. The effect of raloxifene on hip BMD is greater among those with mild to moderate CKD.

show abstract

“…62 CKD mineral and bone disorder (CKD-MBD), characterized by disturbances of calcium/phosphate/parathyroid hormone, bone abnormalities and vascular and soft tissue calcification, are highly prevalent in CKD and are strong, independent predictor of bone fracture, CVD and death. 15,16 Moreover, recent discoveries of fibrogrowth factor (FGF) 23 and klotho shed a new light on calciumphosphate regulation. 63 Huang 64 proposed a working hypothesis of the potential relationship between the effect of klotho on calcium and phosphate metabolism through FGF 23.…”

Section: Bone Disease In Postmenopausal Women With Ckdmentioning

confidence: 99%

“…14 Moreover, the prevalence of low bone mineral densities (BMD) and osteoporosis increases with greater severity of CKD. 15,16 However, data regarding CKD in postmenopausal women are limited. In this review, the association of CKD and CVD, as well as of osteoporosis in postmenopausal women will be discussed.…”

Section: Introductionmentioning

confidence: 99%

Chronic kidney disease in postmenopausal women

Suzuki

Kondo

2011

Hypertens Res

View full text Add to dashboard Cite

Menopause is derived from the Greek words men (month) and pauses (cessation) and means permanent cessation of menstruation after the loss of ovarian activity. Chronic kidney disease (CKD) has recently been associated with cardiovascular events in several studies. CKD patients have a heavy burden of traditional cardiovascular risk factors in addition to a range of nontraditional risk factors such as inflammation and abnormal metabolism of calcium and phosphate. In this review, the association of CKD and cardiovascular disease (CVD), as well as of osteoporosis in postmenopausal women is discussed. CKD mineral and bone disorder, characterized by disturbances of calcium/phosphate/parathyroid hormone, bone abnormalities and vascular and soft tissue calcification, is highly prevalent in CKD and is a strong, independent predictor of bone fracture, CVD and death. Estrogen has been shown to: (a) decrease the expression of angiotensin type 1 receptors in vasculature and kidneys; (b) reduce the expression and activity of angiotensin-converting enzyme, and (c) cause the release of angiotensinogen substrate from the liver. However, the degree of activation or suppression of the renin-angiotensin-aldosterone system by estrogen has not been clearly established. Clinical data on the effects of estrogen therapy on bone mineral densities are extremely limited in the ESRD population. CVD is the most common cause of death in postmenopausal women with CKD and many contributing factors have been explored. INTRODUCTIONMenopause is derived from the Greek words men (month) and pauses (cessation) and means permanent cessation of menstruation after the loss of ovarian activity. Clinically, menopause is defined as the absence of menstruation for 12 months. 1 In clinical medicine, it is well known that menopause is associated with accelerated progression of vascular diseases and osteoporosis as a long-term health risk in women. Indeed, menopausal status increases the risk of cardiovascular disease (CVD) by more than three-fold in women with normal kidney function. 2 Several factors such as the prevalence of hypertension, 3 diabetes, 4 dyslipidemia 5 and so on are known contributors to CVD. In addition to these factors, several studies reveal that chronic kidney disease (CKD) is closely related with CVD events. 6-9 Moreover, Perticone et al. 10 have recently demonstrated that the reduction of estimated glomerular filtration rate (GFR) was associated with the increased risk of death and CVD events, independently of traditional CV risk factors, menopause duration and presence of metabolic syndrome.In addition to these risks in CVD, women lose an average of 25 percent of their bone mass from the time of menopause to age 60, due in large part to the loss of estrogen. Over time, this loss of bone mass can lead to osteoporosis and its related fractures are a serious problem affecting postmenopausal women. 11 Recently, two serious sequels of menopause have been closely associated with CKD. CKD is associated with accelerated progression of CVD, per...

show abstract

Bone mass is related to creatinine clearance in normal elderly women

Cited by 35 publications

References 27 publications

Efficacy and Safety of Denosumab for the Treatment of Osteoporosis in Patients with Chronic Kidney Disease

Efficacy and Safety of Denosumab for the Treatment of Osteoporosis in Patients with Chronic Kidney Disease

The Effect of Raloxifene Treatment in Postmenopausal Women with CKD

Chronic kidney disease in postmenopausal women

Contact Info

Product

Resources

About